1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Xu Q, Zhang TP and Zhao YP: Advances in
early diagnosis and therapy of pancreatic cancer. Hepatobiliary
Pancreat Dis Int. 10:128–135. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Burris HR, Moore MJ, Andersen J, Green MR,
Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM,
Tarassoff P, et al: Improvements in survival and clinical benefit
with gemcitabine as first-line therapy for patients with advanced
pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413.
1997.PubMed/NCBI
|
5
|
He H, Ke R, Lin H, Ying Y, Liu D and Luo
Z: Metformin, an old drug, brings a new era to cancer therapy.
Cancer J. 21:70–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Morales DR and Morris AD: Metformin in
cancer treatment and prevention. Annu Rev Med. 66:17–29. 2015.
View Article : Google Scholar
|
7
|
Kisfalvi K, Moro A, Sinnett-Smith J, Eibl
G and Rozengurt E: Metformin inhibits the growth of human
pancreatic cancer xenografts. Pancreas. 42:781–785. 2013.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS,
Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S and Sarkar FH:
Metformin inhibits cell proliferation, migration and invasion by
attenuating CSC function mediated by deregulating miRNAs in
pancreatic cancer cells. Cancer Prev Res (Phila). 5:355–364. 2012.
View Article : Google Scholar
|
9
|
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and
Xu GM: Metformin induces apoptosis of pancreatic cancer cells.
World J Gastroenterol. 14:7192–7198. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Gao ZY, Liu Z, Bi MH, Zhang JJ, Han ZQ,
Han X, Wang HY, Sun GP and Liu H: Metformin induces apoptosis via a
mitochondria-mediated pathway in human breast cancer cells in
vitro. Exp Ther Med. 11:1700–1706. 2016.PubMed/NCBI
|
11
|
Fujimori T, Kato K, Fujihara S, Iwama H,
Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H,
et al: Antitumor effect of metformin on cholangiocarcinoma: In
vitro and in vivo studies. Oncol Rep. 34:2987–2996. 2015.PubMed/NCBI
|
12
|
Ramjeesingh R, Orr C, Bricks CS, Hopman WM
and Hammad N: A retrospective study on the role of diabetes and
metformin in colorectal cancer disease survival. Curr Oncol.
23:e116–e122. 2016. View Article : Google Scholar : PubMed/NCBI
|
13
|
Owen MR, Doran E and Halestrap AP:
Evidence that metformin exerts its anti-diabetic effects through
inhibition of complex 1 of the mitochondrial respiratory chain.
Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI
|
14
|
El-Mir MY, Nogueira V, Fontaine E, Averet
N, Rigoulet M and Leverve X: Dimetforminhylbiguanide inhibits cell
respiration via an indirect effect targeted on the respiratory
chain complex I. J Biol Chem. 275:223–228. 2000. View Article : Google Scholar : PubMed/NCBI
|
15
|
Gallagher EJ and LeRoith D: Minireview:
IGF, insulin, and cancer. Endoscopy. 152:2546–2255. 2011.
|
16
|
Algire C, Moiseeva O, Deschênes-Simard X,
Amrein L, Petruccelli L, Birman E, Viollet B, Ferbeyre G and Pollak
MN: Metformin reduces endogenous reactive oxygen species and
associated DNA damage. Cancer Prev Res (Phila). 5:536–543. 2012.
View Article : Google Scholar
|
17
|
Hirsch HA, Iliopoulos D and Struhl K:
Metformin inhibits the inflammatory response associated with
cellular transformation and cancer stem cell growth. Proc Natl Acad
Sci USA. 110:972–977. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Gou S, Cui P, Li X, Shi P, Liu T and Wang
C: Low concentrations of metformin selectively inhibit CD133 (+)
cell proliferation in pancreatic cancer and have anticancer action.
Plos One. 8:e639692013. View Article : Google Scholar
|
19
|
Breckenridge DG and Xue D: Regulation of
mitochondrial membrane permeabilization by BCL-2 family proteins
and caspases. Curr Opin Cell Biol. 16:647–652. 2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Yang J, Liu X, Bhalla K, Kim CN, Ibrado
AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by
Bcl-2: Release of cytochrome c from mitochondria blocked. Science.
275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
|
21
|
Amundson SA, Myers TG, Scudiero D, Kitada
S, Reed JC and Fornace AJ Jr: An informatics approach identifying
markers of chemosensitivity in human cancer cell lines. Cancer Res.
60:6101–6610. 2000.PubMed/NCBI
|
22
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Hassan M, Watari H, AbuAlmaaty A, Ohba Y
and Sakuragi N: Apoptosis and molecular targeting therapy in
cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Kim JK and Diehl JA: Nuclear cyclin D1: An
oncogenic driver in human cancer. J Cell Physiol. 220:292–296.
2009. View Article : Google Scholar : PubMed/NCBI
|
25
|
Juríková M, Danihel Ľ, Polák Š and Varga
I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the
diagnosis of breast cancer. Acta Histochem. 30084–30088. 2016.Epub
ahead of print.
|
26
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Colucci G, Labianca R, Di Costanzo F,
Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E,
Sannicolò M, et al: Randomized phase III trial of gemcitabine plus
cisplatin compared with single-agent gemcitabine as first-line
treatment of patients with advanced pancreatic cancer: The GIP-1
study. J Clin Oncol. 28:1645–1651. 2010. View Article : Google Scholar : PubMed/NCBI
|
28
|
Abou-Alfa GK, Letourneau R, Harker G,
Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager
RL, Eckhardt SG and O'Reilly EM: Randomized phase III study of
exatecan and gemcitabine compared with gemcitabine alone in
untreated advanced pancreatic cancer. J Clin Oncol. 24:4441–4447.
2006. View Article : Google Scholar : PubMed/NCBI
|
29
|
Cunningham D, Chau I, Stocken DD, Valle
JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J,
et al: Phase III randomized comparison of gemcitabine versus
gemcitabine plus capecitabine in patients with advanced pancreatic
cancer. J Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Gong J, Robbins LA, Lugea A, Waldron RT,
Jeon CY and Pandol SJ: Diabetes, pancreatic cancer, and metformin
therapy. Front Physiol. 5:4262014. View Article : Google Scholar : PubMed/NCBI
|
31
|
Choi Y, Kim TY, Oh DY, Lee KH, Han SW, Im
SA, Kim TY and Bang YJ: The impact of diabetes mellitus and
metformin treatment on survival of patients with advanced
pancreatic cancer undergoing chemotherapy. Cancer Res Treat.
48:171–179. 2016. View Article : Google Scholar :
|
32
|
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan
M and Li D: Metformin use is associated with better survival of
diabetic patients with pancreatic cancer. Clin Cancer Res.
18:2905–2912. 2012. View Article : Google Scholar : PubMed/NCBI
|
33
|
Zhang JW and Sun Q: Metformin may improve
the prognosis of patients with pancreatic cancer. Asian Pac J
Cancer Prev. 16:3937–3940. 2015. View Article : Google Scholar : PubMed/NCBI
|
34
|
Kordes S, Pollak MN, Zwinderman AH, Mathôt
RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ and Wilmink JW:
Metformin in patients with advanced pancreatic cancer: A
double-blind, randomised, placebo-controlled phase 2 trial. Lancet
Oncol. 16:839–847. 2015. View Article : Google Scholar : PubMed/NCBI
|